NCT00941057 - Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions

Pharmacology, Clinical

Interventions

DRUG

BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium

Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days

DRUG

BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)

Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days

DRUG

BAY 86-7660,levomefolate calcium

Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days

Trial Locations (1)

Neu-Ulm